value <0,05 and r =0,486, p value <0,01 respectively), depressed bronchial resistance SGaw (r =0,773, p value <0,01) and increased RV (r = -0,736, p value <0,01), which determined BO severity. Conclusions: More than half of patients with RA have BO predominantly in terminal bronchioles. Accepting significant decrease of Clara cell protein CC16 in patients with RA having BO we suppose pathogenic relationship between functional depression of Clara cell anti-inflammatory activity and BO in this category of patients. Objectives: To quantify at baseline and 3 years later, the prevalence (at baseline) and incidence (over 3 years) of some selected comorbidities.
Conclusions:
Comorbidities are frequent in RA though screening does not always address the most frequent or severe comorbidities. Efforts must be pursued to improve comorbidity screening and prevention. Background: N-terminal pro-brain natriuretic peptide (NT-proBNP) is a recognized myocardial injure marker, a known predictor of heart failure and cardiovascular death. Rheumatoid arthritis (RA) patients (pts) were shown to have higher than in general population NT-proBNP concentrations, positively correlating with IL-6 levels. Adipose tissue is considered be one of the sources of this pro-inflammatory cytokine. But on the other hand, metabolic syndrome (MS) and obesity, which also occur in RA pts, are usually associated with lower NT-proBNP levels in general population. Objectives: To find out whether overweight/obesity or MS may modify NT-proBNP levels in RA pts. Methods: A total of 68 early RA pts (72% females, 28% males) was enrolled in the study. Mean disease duration was 6 [4;8] months, and RA activity using DAS28 calculator was 5,6 [5,1;6,4] scores. The majority of pts had positive RF (87%) and ACPA (88%). All pts were glucocorticoids and disease-modifying antirheumatic drugs -naïve prior to inclusion. The overweight/obesity was determined by WHO criteria in patients with body mass index (BMI) ≥25 kg/m 2 . National Cholesterol Education Program/Adult Treatment Panel III criteria were used to confirm MS. Serum levels of NT-proBNP (pg/mL) were measured using electrochemiluminescence test Elecsys proBNP II (Roche Diagnostics, Switzerland). NT-proBNP levels >125,0 pg/mL were considered as elevated. Background: In 2011, we started a cardiovascular (CV) risk management program for rheumatoid arthritis (RA) patients visiting Reade in the Netherlands. We previously reported the presence of under treatment of hypercholesterolemia and hypertension [1] . Objectives: To assess the effectiveness of our CV risk management program after one year. Methods: CV risk screening was performed at baseline and we informed the general practitioner (GP) about the results, including advices regarding the initiation of cardio preventive drugs. In high risk patients, antihypertensives were recommended when systolic blood pressure >140 mm/Hg and statins were recommended when low-density lipoprotein >2.5 mmol/l. The decision to start preventive medication was left to the GP. CV risk screening was repeated after one year. Patients completed a questionnaire about the actions that were taken following the results of the initial screening. Results: Of the 266 patients 202 (76%) were female, the mean age was 58±11 years. After one year, 88 out of 134 patients who received inadequate or no treatment at baseline were still untreated or undertreated. Of the 188 (71%) patients who were at high CV risk and who did have an indication to start therapy, only 7.5% was contacted by their GP and another 6.8% arranged an appointment themselves. While the 10-year CV risk did not decrease in the group as a whole, a risk reduction was found in the patients that started medication. Remarkably, 42% of patients reported lifestyle changes, including more exercise (20%), diet adaption (16%) and weight loss (9%). Conclusions: It is striking that one year after the introduction of our CV risk
